ArticleDiscover oncology2025
SLC8A1-AS1 inhibits oral squamous cell carcinoma by regulating the miR-1305/ESRRG axis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSolute carrier family 8 member A1 antisense RNA 1 (SLC8A1-AS1) is a long non-coding RNA (lncRNA) that has been identified in recent years and is implicated in the progression of various cancers, including glioma and thyroid cancer. However, its role in oral squamous cell carcinoma (OSCC) remains poorly understood. The aim of this study is to investigate the function of SLC8A1-AS1 in OSCC and to explore its potential mechanisms of action.
methodsThe TCGA database was utilized to analyze the expression and prognostic significance of SLC8A1-AS1 in OSCC. QRT-PCR was employed to measure the gene expression levels of SLC8A1-AS1 and its target genes. CCK-8, EdU staining, wound healing, and Transwell assays were conducted to assess the effects of SLC8A1-AS1 on OSCC cells. Dual-luciferase reporter gene and RNA pull-down assays were performed to verify the interactions between SLC8A1-AS1 and its target genes. Student’s t-test or one-way analysis of variance (ANOVA) was applied for data analysis in this study.
resultsSLC8A1-AS1 was found to be downregulated in OSCC tissues and cell lines. Overexpression of SLC8A1-AS1 inhbited the proliferation, migration, and invasion of OSCC cells. Bioinformatics analyses predicted that miR-1305 is a target of SLC8A1-AS1, while ESRRG is a target of miR-1305. Furthermore, the inhibitory effects of SLC8A1-AS1 on the proliferation, migration, and invasion of OSCC cells were reversed by the introduction of miR-1305 mimics.
conclusionSLC8A1-AS1 inhibits the progression of OSCC by modulating the miR-1305/ESRRG axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.